Simple search background image

For a more refined search use:Advanced Search

Areas of Study

Incyte's drug discovery efforts were founded in 2002 by a team of world-class scientists striving to create innovative medicines for patients. The rigorous pursuit of scientific excellence remains at the core of our company today.


Our scientific innovation is based on a unique competency in medicinal chemistry, which is seamlessly integrated into a discovery process that is tailored to individual program needs. We have expanded our drug identification efforts to include biotherapeutics, which enables us to access a broad range of oncological drug targets. We continually modify the resourcing of our discovery efforts to maximize information content when and where we need it and ensure that each program, regardless of stage, is executed in the most efficient and data-rich manner possible.

Our discovery approach integrates target selection, portfolio "fit," compound quality, and pharmacodynamic optimization. This approach ensures we not only develop molecules with characteristics optimized for their intended use but also build a portfolio that is strategically coherent and synergy-rich.

Testing tubes


Incyte's targeted therapy discovery strategy emphasizes the prosecution of therapeutic intervention points that lie in interdependent oncogenic pathways. This enables us to readily leverage cross-program knowledge throughout the research and development continuum as well as identify and exploit novel points of synergy.

Inhibitors of JAKPI3K MoleculeFGFR InhibitorsBromodomain ProteinsPan-inhibitor of PIM kinasesLSD1 Inhibitor


Incyte's discovery strategy within the field of immunotherapy is based on the diversity of cells required to maintain an immune-suppressive microenvironment. Immune subversion by cancer cells is mediated by the action of multiple immune-regulatory cell types, and Incyte's discovery capabilities based on both small and large molecule modalities open distinct opportunities to target diverse mechanisms, including: IDO1, JAK, PI3Kδ, OX40, PD-1, and GITR.

IDO1 inhibitorSelective arginase inhibitorPD-1 antibodyGITR moleculeOX40 Agonist AntibodiesAntagonistic anti-TIM-3 antibodyLAG-3 moleculeSmall molecule inhibitor of AXL and MERInhibitors of JAK


Inhibitors of JAK

Copyright 2023 Incyte

Powered by: